Analyst Price Targets — IRD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 9, 2026 7:37 pm | — | Oppenheimer | $20.00 | $5.73 | TheFly | Opus Genetics price target raised to $20 from $10 at Oppenheimer |
| September 9, 2026 5:35 pm | Andreas Argyrides | Chardan Capital | $16.00 | $5.67 | TheFly | Opus Genetics price target raised to $16 from $13 at Chardan |
| August 7, 2026 12:24 pm | — | RBC Capital | $9.00 | $3.63 | TheFly | Opus Genetics price target lowered to $9 from $10 at RBC Capital |
| June 23, 2026 10:45 am | — | RBC Capital | $10.00 | $4.08 | TheFly | Opus Genetics initiated with an Outperform at RBC Capital |
| June 17, 2026 10:49 am | Matthew Caufield | H.C. Wainwright | $8.00 | $3.90 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD) |
| May 21, 2026 10:25 am | — | Leerink Partners | $10.00 | $4.44 | TheFly | Opus Genetics initiated with an Outperform at Leerink |
| March 11, 2026 1:17 pm | Albert Love | Craig-Hallum | $9.00 | $4.99 | StreetInsider | Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity" |
| January 20, 2026 10:44 am | Thomas Shrader | BTIG | $7.00 | $2.10 | TheFly | Opus Genetics initiated with a Buy at BTIG |
| November 25, 2025 10:16 am | — | Piper Sandler | $7.00 | $2.00 | TheFly | Opus Genetics initiated with an Overweight at Piper Sandler |
Latest News for IRD
Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 330,783 shares of the company's stock, valued at approximately $1,360,000. Squarepoint Ops LLC owned about 0.40% of Opus
Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements and strong safety in all Cohort 1 patients, with greater gains in less advanced disease. IRD's pipeline targets large, underserved markets with no approved therapies; cash runway extends into 2029, supporting ongoing…
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Opus Genetics, Inc. (NASDAQ:IRD) stock is surging on Wednesday after the company reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1.
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual function, with structural improvements observed in four participants FDA aligned on ≥3 decibels microperimetry improvement in conjunction with patient reported outcomes as a potential pivotal endpoint…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRD.
U.S. House Trading
No House trades found for IRD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.